Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Deffered Revenue: 2010-2018

Historic Non-Current Deffered Revenue for Altimmune (ALT) over the last 3 years, with Dec 2018 value amounting to $1.0 million.

  • Altimmune's Non-Current Deffered Revenue rose 170.59% to $1.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.0 million, marking a year-over-year increase of 170.59%. This contributed to the annual value of $1.0 million for FY2018, which is 170.59% up from last year.
  • Per Altimmune's latest filing, its Non-Current Deffered Revenue stood at $1.0 million for Q4 2018, which was down 4.07% from $1.1 million recorded in Q3 2018.
  • Altimmune's 5-year Non-Current Deffered Revenue high stood at $1.1 million for Q2 2018, and its period low was $164,609 during Q3 2017.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $716,148 (2017), whereas its average is $661,060.
  • Data for Altimmune's Non-Current Deffered Revenue shows a peak YoY soared of 569.18% (in 2018) over the last 5 years.
  • Altimmune's Non-Current Deffered Revenue (Quarterly) stood at $179,424 in 2016, then spiked by 115.41% to $386,489 in 2017, then surged by 170.59% to $1.0 million in 2018.
  • Its last three reported values are $1.0 million in Q4 2018, $1.1 million for Q3 2018, and $1.1 million during Q2 2018.